Phillips B G, Bauman J L
Section of Cardiovascular Pharmacotherapy, College of Pharmacy, University of Illinois at Chicago, USA.
Pharmacoeconomics. 1995 Jun;7(6):521-33. doi: 10.2165/00019053-199507060-00006.
Considerable progress has been made regarding the treatment of atrial fibrillation and atrial flutter. However, controversies still exist with respect to the therapy of choice for ventricular rate control, requirements for long term preventive therapy, and the place of surgical and ablation alternatives. Surrounding these controversies also lies a paucity of pharmacoeconomic studies, which limits delineation of the most cost-effective therapy for patients with atrial fibrillation and atrial flutter. This article reviews prescribing trends in the US for antiarrhythmic agents, and the available pharmacoeconomic studies that have specifically addressed the treatment of atrial fibrillation and atrial flutter.
在心房颤动和心房扑动的治疗方面已取得了相当大的进展。然而，在心室率控制的首选治疗方法、长期预防性治疗的要求以及手术和消融替代方案的地位等方面仍存在争议。围绕这些争议还存在药物经济学研究的匮乏，这限制了对心房颤动和心房扑动患者最具成本效益治疗方法的界定。本文回顾了美国抗心律失常药物的处方趋势，以及专门针对心房颤动和心房扑动治疗的现有药物经济学研究。
